By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit

Key Statistics

Ownership: Public

Web Site: Idera Pharma
Symbol: IDRA

Company News
Idera Pharma (IDRA) Announces Pricing Of Public Offering Of Common Stock 10/7/2016 10:29:02 AM
Idera Pharma (IDRA) Announces Proposed Public Offering Of Common Stock 10/6/2016 7:27:07 AM
Idera Pharma (IDRA) Presents New Third Generation Antisense (3GA) Data At The 12th Annual Meeting Of The Oligonucleotide Therapeutics Society 9/27/2016 7:43:09 AM
Idera Pharma (IDRA) Reports Promising Data From Ongoing Phase I Dose Escalation In Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma 9/26/2016 7:51:20 AM
Idera Pharma (IDRA) Presents The Novel Mechanism Of Action Of Its Third Generation Antisense Technology 8/24/2016 7:45:47 AM
Idera Pharma (IDRA) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/2/2016 8:24:19 AM
Idera Pharma (IDRA) Announces Initiation Of Phase I/II Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With Metastatic Melanoma 12/14/2015 7:39:36 AM
Idera Pharma (IDRA) Reports Positive Data From Ongoing Phase 1/2 Clinical Trial Of IMO-8400 In Patients With Waldenstrom’s Macroglobulinemia 12/7/2015 12:09:40 PM
Idera Pharma (IDRA) Forges Renal Deal Worth $100 Million+ Deal with GlaxoSmithKline (GSK) 11/23/2015 10:10:40 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Appointment Of Joanna Horobin As Chief Medical Officer 11/18/2015 10:31:52 AM